KRAS and colorectal carcinoma: The limited response of CRC patients to KRASG12C inhibitors may be attributed to multiple mechanisms of resistance, both upstream and downstream of KRAS as well as co-lateral pathways (e.g., Wnt/β-catenin) that can compensate for the effects of a mutant specific KRAS inhibitor.